New Delhi: Drug price controller National Pharmaceutical Pricing Authority (NPPA) will conduct a nation -wide census on drug firms in the country for providing insights to the government for future policy making and planning.
The First Pharmaceutical Industry Census (FPCI) intends to generate pharma map of India after gathering information on various aspects including investments, pricing and product specifications, as well as compliance to good manufacturing practices by drug makers in the country.
“The proposed census would cover more than 10,000 drug manufacturing units in the country through a structured questionnaire so as to provide insights for policy making and planning. NPPA would publish the census data and would send it to various ministries for their reference and future actions,” said Ashok Kumar, chairman, NPPA.
He said the government has allocated Rs54 lakh in the phase I for conducting the census. NPPA would conduct the census in association with 4th All India Census of Micro, Small and Medium Enterprises.
Chemicals and Fertilisers Minister Ram Vilas Paswan, who was presiding over an NPPA function, on Thursday gave his go ahead to FPCI.
“FPCI would commence during the current fiscal and would be concluded during the next fiscal,” Paswan said.
He said the census would create a database regarding turnover of pharmaceutical manufacturing units in the country by class of industry, state-wise and district wise and also by type of units (formulation and bulk among others).
The minister also kick started NPPA’s new initiative aimed at creating consumer awareness on various aspects including overcharging of drugs by manufacturers, sales without prior price approval and non-availability or shortage of any medicine.
“The initiative would disseminate information about prices and availability of scheduled drugs and formulations to benefit the consumers,” Paswan said.
Consumers would be able to file complaint against an individual or an organisation through NPPA website, based on which the authority would initiate an action within 30 days.
“Those consumers whose complaints are found to be genuine would get a cash reward of Rs 1,000,” Paswan said.
NPPA unveiled a directory of 10,563 drug manufacturing units in the country.